where the 50 Best presentations made at ASCO will be presented by Members of the Scientific Committee. They will be presented and commented by different speakers.) Herein, I'd like to introduce these abstracts to the readers briefly. Among these, the most notable study was GOG 218 evaluating whether there is therapeutic impact from concurrent±main-tenance bevacizumab (BEV) with standard chemotherapy (CP) in patients with stage III-IV epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian cancer (FC). 1 All women underwent abdominal surgery for staging and maximal tumor debulking before being randomly assigned to one of three treatment arms: 1) CP plus placebo during the induction phase (cycles 1 to 6), followed by placebo maintenance (cycles 7 to 22); 2) CP plus concurrent bevacizumab during induction, followed by placebo maintenance; and 3) CP plus concurrent bevacizumab during induction, followed by bevacizumab maintenance. Bevacizumab was not administered during the first 21-day induction cycle so as to limit postsurgical bleeding complications. The entire treatment schedule took 15 months to complete. Although overall survival was originally selected as the primary endpoint, this was changed to progression-free survival (PFS) to accord with international consensus as a more appropriate endpoint for frontline phase III trials in this patient population, as well as pressure by patients to unblind their treatment assignment in the event of disease progression. 
